Historically, vaccines have been our best weapon against the world’s deadliest infectious diseases, including smallpox, polio, measles, and yellow fever. Unfortunately, we do not have a vaccine for HIV. The virus has unique ways of evading the immune system, and the human body seems incapable of mounting an effective immune response against it. As a result, scientists do not have a clear picture of what is needed to provide protection against HIV.
Finding a safe, effective, and durable HIV vaccine remains a top priority for NIAID. Through the Vaccine Research Center and the Division of AIDS, NIAID conducts and supports biomedical research that leads to increased knowledge about how HIV interacts with the human immune system and evaluation of the most promising vaccine candidates. Although a vaccine to prevent HIV infection remains the ultimate goal, NIAID is also examining vaccines that could significantly alter the course of disease and infectiousness of people infected with HIV, which could provide positive health benefits both for infected individuals and the larger community.
NIH-Sponsored HIV Vaccine Trial Launches in South Africa—Feb. 18, 2015
Media Availability: Powerful HIV Antibodies May Require Assist from Second Antibody to Develop—July 24, 2014
Meetings Resources, Best Practices in Mucosal Sampling—May 1, 2014
Media Availability: NIH Grantees Sharpen Understanding of Antibodies that May Cut Risk of HIV Infection—March 19, 2014
Media Availability: Study of Antibody Evolution Charts Course toward HIV Vaccine—March 3, 2014
Last Updated February 19, 2015